为肝细胞癌武装 GPC3 CAR T 细胞:多少才足够,下一步是什么?
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
英文原题:Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency.
此外,肿瘤微环境中酸性触发的卡托普利释放可将促肿瘤N2表型中性粒细胞极化为抗肿瘤N1表型,从而增强免疫效应,在H22荷瘤小鼠中实现83%的完全肿瘤消退并延长生存时间。
肝细胞癌(HCC)通常以免疫“冷”状态出现,随后通过TIL(肿瘤浸润淋巴细胞)保护其免受细胞溶解攻击,导致对免疫治疗反应不佳。在此,我们探索了一种基于酸性/光敏树突状细胞(DCs)的新抗原纳米疫苗,以将肿瘤免疫“冷”状态转化为“热”状态,并重塑肿瘤相关中性粒细胞以增强抗癌免疫反应,从而提高免疫治疗效率。该纳米疫苗由SiPCCl2杂化介孔二氧化硅与Fe(III)-卡托普利配位构建,并包覆经H22特异性新抗原刺激的成熟DCs外泌膜。纳米疫苗主动靶向H22肿瘤,并通过光动力疗法产生过量1O2诱导免疫原性细胞死亡,促进肿瘤相关抗原释放,从而作为原位肿瘤疫苗增强抗肿瘤T细胞反应,抑制原发性H22肿瘤生长。有趣的是,纳米疫苗也归巢至淋巴结,直接诱导新抗原特异性T细胞的激活和增殖,以抑制原发/远端肿瘤生长。此外,肿瘤微环境中酸性触发的卡托普利释放可将促肿瘤N2表型中性粒细胞极化为抗肿瘤N1表型,从而改善免疫效果,在H22荷瘤小鼠中实现完全肿瘤消退(83%)并延长生存时间。这项工作为开发新型HCC免疫治疗策略提供了替代方法。
Hepatocellular carcinoma (HCC) commonly emerges in an immunologically "cold" state, thereafter protects it away from cytolytic attack by tumor-infiltrating lymphocytes, resulting in poor response to immunotherapy. Herein, an acidic/photo-sensitive dendritic cell (DCs)-based neoantigen nano-vaccine has been explored to convert tumor immune "cold" state into "hot", and remodel tumor-associated neutrophils to potentiate anticancer immune response for enhancing immunotherapy efficiency. The nano-vaccine is constructed by SiPCCl 2 -hybridized mesoporous silica with coordination of Fe(III)-captopril, and coating with exfoliated membrane of matured DCs by H22-specific neoantigen stimulation. The nano-vaccines actively target H22 tumors and induce immunological cell death to boost tumor-associated antigen release by the generation of excess 1 O 2 through photodynamic therapy, which act as in situ tumor vaccination to strengthen antitumor T-cell response against primary H22 tumor growth. Interestingly, the nano-vaccines are also home to lymph nodes to directly induce the activation and proliferation of neoantigen-specific T cells to suppress the primary/distal tumor growth. Moreover, the acidic-triggered captopril release in tumor microenvironment can polarize the protumoral N2 phenotype neutrophils to antitumor N1 phenotype for improving the immune effects to achieve complete tumor regression (83%) in H22-bearing mice and prolong the survival time. This work provides an alternative approach for developing novel HCC immunotherapy strategies.
MEMBER ACCOUNT
登录成功会直接打开下一页。